LogoPeqSERPE
logoCabeceraNinos

Hemos leído sobre ... Miopatías inflamatorias

Última actualización: 08 Noviembre 2019
 
 
OCTUBRE 2019
  • Oldroyd A, Little MA, Dixon W, Chinoy H.
    A review of accelerometer-derived physical activity in the idiopathic inflammatory myopathies
    BMC Rheumatol. 2019 Oct 21;3:41. doi: 10.1186/s41927-019-0088-1. eCollection 2019.
    https://www.ncbi.nlm.nih.gov/pubmed/31660533
  • Gitiaux C, Bondet V, Bekaddour N, Nusbaum P, Hubas A, Melki I, Bodemer C, Quartier P, Desguerre I, Crow YJ, Herbeuval JP, Duffy D, Bader Meunier B, Rodero MP.
    Inhibition of IFNα secretion in cells from patients with juvenile dermatomyositis under TBK1 inhibitor treatment revealed by single-molecular assay technology
    Rheumatology (Oxford). 2019 Oct 30. pii: kez508. doi: 10.1093/rheumatology/kez508. [Epub ahead of print]

    https://www.ncbi.nlm.nih.gov/pubmed/31665500
 
SEPTIEMBRE 2019
  • Nordal E, Pistorio A, Rygg M, Giancane G, Maghnie M, Di Iorgi N, Flemming K, Hofer M, Melo-Gomes JA, Bica BERG, Brunner J, Dannecker G, Gerloni V, Harjacek M, Huppertz HI, Pratsidou-Gertsi P, Nielsen S, Stanevicha V, Ten Cate R, Vougiouka O, Pastore S, Simonini G, Ravelli A, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO).
    Growth and puberty in juvenile dermatomyositis: a longitudinal cohort study.
    Arthritis Care Res (Hoboken). 2019 Sep 10. doi: 10.1002/acr.24065. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/31507092
  • Wu JQ, Lu MP, Reed AM.
    Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.
    World J Pediatr. 2019 Sep 26. doi: 10.1007/s12519-019-00313-8. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/31556011
 
AGOSTO 2019
  • Duvvuri B, Pachman LM, Morgan G, Khojah AM, Klein-Gitelman M, Curran ML, Doty S, Lood C.
    Neutrophil Extracellular Traps in Tissue and Periphery in Juvenile Dermatomyositis.
    Arthritis Rheumatol. 2019 Aug 12. doi: 10.1002/art.41078.
    https://www.ncbi.nlm.nih.gov/pubmed/31403247
  • Patwardhan A, Spencer CH.
    Biologics in refractory myositis: experience in juvenile vs. adult myositis; part II: emerging biologic and other therapies on the horizon.
    Pediatr Rheumatol Online J. 2019 Aug 20;17(1):56.
    https://www.ncbi.nlm.nih.gov/pubmed/31429786
 
JULIO 2019
  •  Sabbagh S, Pinal-Fernandez I, Kishi T, Targoff IN, Miller FW, Rider LG, Mammen AL.
    Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis.
    Ann Rheum Dis. 2019 Jul;78(7):988-995
    https://ard.bmj.com/content/78/7/988
  • Rosina S, Consolaro A, van Dijkhuizen P, Pistorio A, Camilla Varnier G, Bovis F et al.
    Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis.
    Rheumatology (Oxford). 2019 Jul;58(7):1196-1205.
    https://doi.org/10.1093/rheumatology/key421
  • Leclair V, Galindo-Feria AS, Dastmalchi M, Holmqvist M, Lundberg IE.
    Efficacy and safety of rituximab in anti-synthetase antibody positive and negative subjects with idiopathic inflammatory myopathy: a registry-based study.
    Rheumatology (Oxford). 2019 Jul 1;58(7):1214-1220.
    https://www.ncbi.nlm.nih.gov/pubmed/30690633
  • Rothwell S, Chinoy H, Lamb JA, Miller FW, Rider LG, Wedderburn LR, et al; Myositis Genetics Consortium (MYOGEN).
    Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups.
    Ann Rheum Dis. 2019 Jul;78(7):996-1002.
    https://www.ncbi.nlm.nih.gov/pubmed/31138531
  • Wilkinson MGL, Radziszewska A, Wincup C, Ioannou Y, Isenberg DA, Manson JJ, Jury EC.
    Using peripheral blood immune signatures to stratify patients with adult and juvenile inflammatory myopathies.
    Rheumatology (Oxford). 2019 Jul 10. pii: kez252. doi: 10.1093/rheumatology/kez252. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/31292651
 
JUNIO 2019
  • Tsaltskan V, Aldous A, Serafi S, Yakovleva A, Sami H, Mamyrova G, Targoff IN, Schiffenbauer A, Miller FW, Simmens SJ, Curiel R, Jones OY, Rider LG.
    Long-term outcomes in Juvenile Myositis patients.
    Semin Arthritis Rheum. 2019 Jun 28. pii: S0049-0172(19)30136-2. doi: 10.1016/j.semarthrit.2019.06.014. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/31303436
 
ABRIL 2019
  • Mizuta M, Shimizu M, Inoue N, Nakagishi Y, Yachie A
    Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome.
    Cytokine. 2019 Apr 2;119:182-187.
    https://www.ncbi.nlm.nih.gov/pubmed/30952065
 
MARZO 2019
  • Chamseddin B, Marks E, Dominguez A, Wysocki C, Vandergriff T.
    Refractory Macrophage Activation Syndrome in the setting of Adult Onset Still's Disease with Hemophagocytic Lymphohistiocytosis Detected on Skin Biopsy treated with Canakinumab and Tacrolimus.
    J Cutan Pathol. 2019 Mar 30. doi: 10.1111/cup.13466. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30927277
  • Papadopoulou C, Hong Y, Omoyinmi E, Brogan PA, Eleftheriou D.
    Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis.
    Brain. 2019 Mar 1;142(3):e8.
    https://www.ncbi.nlm.nih.gov/pubmed/30715143
  • Pinto B, Janardana R, Nadig R, Mahadevan A, Bhatt AS, Raj JM, Shobha V.
    Comparison of the 2017 EULAR/ACR criteria with Bohan and Peter criteria for the classification of idiopathic inflammatory myopathies.
    Clin Rheumatol. 2019 Mar 22. doi: 10.1007/s10067-019-04512-6. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30903308
  • Ukichi T, Yoshida K, Matsushima S, Kawakami G, Noda K, Furuya K, Kurosaka D.
    MRI of skeletal muscles in patients with idiopathic inflammatory myopathies: characteristic findings and diagnostic performance in dermatomyositis.
    RMD Open. 2019 Mar 28;5(1):e000850.
    https://www.ncbi.nlm.nih.gov/pubmed/30997152
 
ENERO 2019
  • Rosina S, Consolaro A, van Dijkhuizen P, Pistorio A, Varnier GC, Bovis F, Nistala K, Maillard S, Civino A, Tsitsami E, de Inocencio J, Jelusic M, Vojinovic J, Espada G, Makay B, Katsicas MM, Pratsidou-Gertsi P, Lazarevic D, Rao AP, Pires Marafon D, Martini A, Pilkington C, Ruperto N, Ravelli A.
    Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis.
    Rheumatology (Oxford). 2019 Jan 23. doi: 10.1093/rheumatology/key421. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30690571
 
DICIEMBRE 2018
  • Wienke J, Deakin CT, Wedderburn LR, van Wijk F, van Royen-Kerkhof A.
    Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools.
    Front Immunol. 2018 Dec 18;9:2951. doi: 10.3389/fimmu.2018.02951.
    https://www.ncbi.nlm.nih.gov/pubmed/30619311
  • Orandi AB, Dharnidharka VR, Al-Hammadi N, Baszis KW; CARRA Legacy Registry Investigators.
    Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis.
    Pediatr Rheumatol Online J. 2018 Dec 29;16(1):84. doi: 10.1186/s12969-018-0299-9.
    https://www.ncbi.nlm.nih.gov/pubmed/30594206
  • Moneta GM, Pires Marafon D, Marasco E, Rosina S, Verardo M, Fiorillo C, Minetti C, Bracci-Laudiero L, Ravelli A, De Benedetti F, Nicolai R.
    Muscle Expression of Type I and Type II Interferons Is Increased in Juvenile Dermatomyositis and Related to Clinical and Histological Features.
    Arthritis Rheumatol. 2018 Dec 15. doi: 10.1002/art.40800. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30552836
 
OCTUBRE 2018
  • Yasin SA, Schutz PW, Deakin CT, Sag E, Varsani H, Simou S, Marshall LR, Tansley SL, McHugh NJ, Holton JL, Wedderburn LR, Jacques TS; UK Juvenile Dermatomyositis Research Group (UK-Ireland).
    Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features
    Neuropathol Appl Neurobiol. 2018 Oct 31. doi: 10.1111/nan.12528. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/30378704
  • Huber AM.
    Update on the clinical management of juvenile dermatomyositis.
    Expert Rev Clin Immunol. 2018 Oct 11:1-8. doi: 10.1080/1744666X.2018.1535901. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30308133
 
SEPTIEMBRE 2018
  • Faguer S, Belliere J, Ribes D.
    Complement C5-blocking Agent in Refractory Dermatomyositis.
    J Rheumatol. 2018 Sep 15. pii: jrheum.180060. doi: 10.3899/jrheum.180060. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30219762
  • Kubínová K, Dejthevaporn R, Mann H, Machado PM, Vencovský J.
    The role of imaging in evaluating patients with idiopathic inflammatory myopathies.
    Clin Exp Rheumatol. 2018 Sep-Oct;36 Suppl 114(5):74-81.
    https://www.ncbi.nlm.nih.gov/pubmed/30296982
  • Thyoka M, Adekunle O, Pilkington C, Walters S, Arthurs OJ, Humphries P, Johnson K, Kraft J, Landes C, Persaud T, Sinha R, Offiah AC.
    Introduction of a novel magnetic resonance imaging-based scoring system for assessing disease activity in children with juvenile dermatomyositis.
    Rheumatology (Oxford). 2018 Sep 1;57(9):1661-1668
    https://www.ncbi.nlm.nih.gov/pubmed/29901756
  • Mecoli CA, Park JK, Alexanderson H, Regardt M, Needham M, de Groot I, Sarver C, Lundberg IE, Shea B, de Visser M, Song YW, Bingham CO 3rd, Christopher-Stine L.
    Perceptions of Patients, Caregivers, and Healthcare Providers of Idiopathic Inflammatory Myopathies: An International OMERACT Study.
    J Rheumatol. 2018 Sep 15. pii: jrheum.180353. doi: 10.3899/jrheum.180353. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30219767
  • Mariampillai K, Granger B, Amelin D, Guiguet M, Hachulla E, Maurier F, Meyer A, Tohmé A, Charuel JL, Musset L, Allenbach Y, Benveniste O.
    Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies.
    JAMA Neurol. 2018 Sep 10. doi: 10.1001/jamaneurol.2018.2598. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30208379
  • Vuillard C, Pineton de Chambrun M, de Prost N, Guérin C, Schmidt M, Dargent A, Quenot JP, Préau S, Ledoux G, Neuville M, Voiriot G, Fartoukh M, Coudroy R, Dumas G, Maury E, Terzi N, Tandjaoui-Lambiotte Y, Schneider F, Grall M, Guérot E, Larcher R, Ricome S, Le Mao R, Colin G, Guitton C, Zafrani L, Morawiec E, Dubert M, Pajot O, Mentec H, Plantefève G, Contou D.
    Clinical features and outcome of patients with acute respiratory failure revealing anti-synthetase or anti-MDA-5 dermato-pulmonary syndrome: a French multicenter retrospective study.
    Ann Intensive Care. 2018 Sep 11;8(1):87
    https://www.ncbi.nlm.nih.gov/pubmed/30203297
 
AGOSTO 2018
  • van Dijkhuizen EHP, De Iorio M, Wedderburn LR, Deakin CT; JDRG.
    Clinical signs and symptoms in a joint model of four disease activity parameters in juvenile dermatomyositis: a prospective, longitudinal, multicenter cohort study.
    Arthritis Res Ther. 2018 Aug 15;20(1):180. doi: 10.1186/s13075-018-1687-8.
    https://www.ncbi.nlm.nih.gov/pubmed/30111380
  • Huber AM.
    Juvenile Idiopathic Inflammatory Myopathies.
    Pediatr Clin North Am. 2018 Aug;65(4):739-756. doi: 10.1016/j.pcl.2018.04.006.
    https://www.ncbi.nlm.nih.gov/pubmed/30031496
  • Varnier GC, Pilkington CA, Wedderburn LR.
    Juvenile dermatomyositis: novel treatment approaches and outcomes.
    Curr Opin Rheumatol. 2018 Aug 16. doi: 10.1097/BOR.0000000000000538. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30124602
  • Sakurai N, Hino-Shishikura A, Nozawa T, Kamide H, Ohara A, Nishimura K, Kikuchi M, Hara R, Mori M, Ito S.
    Clinical significance of subcutaneous fat and fascial involvement in juvenile dermatomyositis.
    Mod Rheumatol. 2018 Aug 10:1-16. doi: 10.1080/14397595.2018.1511026. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30092673
  • Liphaus BL, Sallum AEM, Aikawa NE, Kiss MHB, Carrasco S, Palmeira P, Lima L, Silva CA, Goldenstein-Schainberg C, Carneiro-Sampaio M.
    Increased Soluble Cytoplasmic Bcl-2 Protein Serum Levels and Expression and Decreased Fas Expression in Lymphocytes and Monocytes in Juvenile Dermatomyositis.
    J Rheumatol. 2018 Aug 1. pii: jrheum.171248. doi: 10.3899/jrheum.171248. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30068766
 
JULIO 2018
  • Mamyrova G, Kishi T, Targoff IN, Ehrlich A, Curiel RV, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group.
    Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis.
    Rheumatology (Oxford). 2018 Jul 16. doi: 10.1093/rheumatology/key190. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30016492
 
JUNIO 2018
  • Barth Z, Schwartz T, Flatø B, Aaløkken TM, Koller A, Lund MB, Sjaastad I, Sanner H.
    The Association Between Nailfold Capillary Density and Pulmonary and Cardiac Involvement in Medium- to Long-standing Juvenile Dermatomyositis.
    Arthritis Care Res (Hoboken). 2018 Jun 28. doi: 10.1002/acr.23687
    https://www.ncbi.nlm.nih.gov/pubmed/29953739
  • Jindal AK, Guleria S, Pilania RK, Bishnoi A, Vinay K, Dogra S, Suri D, Rawat A, Singh S.
    Inverse Gottron papules in juvenile dermatomyositis: an under recognized clinical entity.
    Rheumatol Int. 2018 Jun;38(6):1153-1160. doi: 10.1007/s00296-018-4038-9
    https://www.ncbi.nlm.nih.gov/pubmed/29721695
 
MAYO 2018
  • Deakin CT, Campanilho-Marques R, Simou S, Moraitis E, Wedderburn LR, Pullenayegum E, Pilkington CA; Juvenile Dermatomyositis Research Group.
    Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling.
    Arthritis Rheumatol. 2018 May;70(5):785-793. doi: 10.1002/art.40418.
    https://www.ncbi.nlm.nih.gov/pubmed/29342499
  • Rider LG, Aggarwal R, Machado PM, Hogrel JY, Reed AM, Christopher-Stine L, Ruperto N.
    Update on outcome assessment in myositis.
    Nat Rev Rheumatol. 2018 May;14(5):303-318. doi: 10.1038/nrrheum.2018.33. Epub 2018 Apr 12.
    https://www.ncbi.nlm.nih.gov/pubmed/29651119
  • Barth Z, Witczak BN, Flatø B, Koller A, Sjaastad I, Sanner H.
    Assessment of Microvascular Abnormalities by Nailfold Capillaroscopy in Juvenile Dermatomyositis After Medium- to Long-Term Followup.
    Arthritis Care Res (Hoboken). 2018 May;70(5):768-776. doi: 10.1002/acr.23338. Epub 2018 Mar 23.
    https://www.ncbi.nlm.nih.gov/pubmed/28805016
  • Aouizerate J, De Antonio M, Bader-Meunier B, Barnerias C, Bodemer C, Isapof A, Quartier P, Melki I, Charuel JL, Bassez G, Desguerre I, Gherardi RK, Authier FJ, Gitiaux C.
    Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis.
    Rheumatology (Oxford). 2018 May 1;57(5):873-879. doi: 10.1093/rheumatology/kex516.
    https://www.ncbi.nlm.nih.gov/pubmed/29474663
 
ABRIL 2018
  • Keller S, Golsari A, Yamamura J.
    Juvenile Dermatomyositis.
    Rofo. 2018 Apr 26. doi: 10.1055/a-0591-5552. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/29698985
  • Tory HO, Carrasco R, Griffin T, Huber AM, Kahn P, Robinson AB, Zurakowski D, Kim S; CARRA Juvenile Dermatomyositis Quality Measures Workgroup.
    Comparing the importance of quality measurement themes in juvenile idiopathic inflammatory myositis between patients and families and healthcare professionals.
    Pediatr Rheumatol Online J. 2018 Apr 19;16(1):28. doi: 10.1186/s12969-018-0248-7.
    https://www.ncbi.nlm.nih.gov/pubmed/29673367
  • Rosina S, Varnier GC, Mazzoni M, Lanni S, Malattia C, Ravelli A.
    Innovative Research Design to Meet the Challenges of Clinical Trials for JuvenileDermatomyositis.
    Curr Rheumatol Rep. 2018 Apr 10;20(5):29. doi: 10.1007/s11926-018-0734-4.
    https://www.ncbi.nlm.nih.gov/pubmed/29637406
  • Ueki M, Kobayashi I, Takezaki S, Tozawa Y, Okura Y, Yamada M, Kuwana M, Ariga T.
    Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies.
    Mod Rheumatol. 2018 Apr 9:1-6. doi: 10.1080/14397595.2018.1452353. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/29532710
  • Aouizerate J, De Antonio M, Bader-Meunier B, Barnerias C, Bodemer C, Isapof A, Quartier P, Melki I, Charuel JL, Bassez G, Desguerre I, Gherardi RK, Authier FJ, Gitiaux C.
    Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juveniledermatomyositis.
    Rheumatology (Oxford). 2018 May 1;57(5):873-879. doi:10.1093/rheumatology/kex516.
    https://www.ncbi.nlm.nih.gov/pubmed/29474663
  • Karasawa R, Tamaki M, Sato T, Tanaka M, Nawa M, Yudoh K, Jarvis JN.
    Multiple target autoantigens on endothelial cells identified in juvenile dermatomyositis using proteomics.
    Rheumatology (Oxford). 2018 Apr 1;57(4):671-676. doi: 10.1093/rheumatology/kex468.
    https://www.ncbi.nlm.nih.gov/pubmed/29361142
  • Rider LG, Aggarwal R, Machado PM, Hogrel JY, Reed AM, Christopher-Stine L, Ruperto N.
    Update on outcome assessment in myositis.
    Nat Rev Rheumatol. 2018 May;14(5):303-318. doi: 10.1038/nrrheum.2018.33. Epub 2018 Apr 12.
    https://www.ncbi.nlm.nih.gov/pubmed/29651119
 
MARZO 2018
  • Ueki M, Kobayashi I, Takezaki S, Tozawa Y, Okura Y, Yamada M, Kuwana M, Ariga T.
    Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies.
    Mod Rheumatol. 2018 Mar 13:1-16.
    https://www.ncbi.nlm.nih.gov/pubmed/29532710
  • Santos-Briz A, Calle A, Linos K, Semans B, Carlson A, Sangüeza OP, Metze D, Cerroni L, Díaz-Recuero JL, Alegría-Landa V, Mascaró JM, Moreno C, Rodríguez-Peralto JL, Requena L.
    Dermatomyositis panniculitis: a clinicopathological and immunohistochemical study of 18 cases.
    J Eur Acad Dermatol Venereol. 2018 Mar 10. doi: 10.1111/jdv.14932. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/29524269
 
FEBRERO 2018
  • Miyamae T, Hara T, Hanaya A, Tani Y, Kishi T, Yamanaka H.
    Effect of Adalimumab on Refractory Arthritis in Juvenile Idiopathic Inflammatory Myopathy with Anti-MDA5 Autoantibody.
    Case Rep Rheumatol. 2018 Feb 6;2018:2164312. doi: 10.1155/2018/2164312. eCollection 2018.
    https://www.ncbi.nlm.nih.gov/pubmed/29552370
 
ENERO 2018
  • Yeker RM, Pinal-Fernandez I, Kishi T, Pak K, Targoff IN, Miller FW, Rider LG, Mammen AL; Childhood Myositis Heterogeneity Collaborative Study Group.
    Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenilemyositis.
    Ann Rheum Dis. 2018 Jan 23. pii: annrheumdis-2017-212436. doi: 10.1136/annrheumdis-2017-212436. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/29363513
  • Deakin CT, Campanilho-Marques R, Simou S, Moraitis E, Wedderburn LR, Pullenayegum E, Pilkington CA; Juvenile Dermatomyositis Research Group (JDRG).
    Efficacy and safety of cyclophosphamide treatment in severe juvenile dermatomyositis shown by marginal structural modelling.
    Arthritis Rheumatol. 2018 Jan 17. doi: 10.1002/art.40418. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/29342499
  • Silverberg JI, Kwa L, Kwa MC, Laumann AE, Ardalan K.
    Cardiovascular and cerebrovascular comorbidities of juvenile dermatomyositis in US children: an analysis of the National Inpatient Sample.
    Rheumatology (Oxford). 2018 Jan 24. doi: 10.1093/rheumatology/kex465. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/29373707
  • Karasawa R, Tamaki M, Sato T, Tanaka M, Nawa M, Yudoh K, Jarvis JN.
    Multiple target autoantigens on endothelial cells identified in juvenile dermatomyositis using proteomics.
    Rheumatology (Oxford). 2018 Jan 18. doi: 10.1093/rheumatology/kex468. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/29361142
 
DICIEMBRE 2017
  • Lundberg IE, Tjärnlund A, Bottai M The International Myositis Classification Criteria Project consortium, The Euromyositis register and The Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland), et al.
    2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups
    Ann Rheum Dis. 2017 Dec;76(12):1955-1964.
    https://www.ncbi.nlm.nih.gov/pubmed/29106061
  • Varnier GC, Rosina S, Ferrari C, Pistorio A, Consolaro A, Bovis F, Dalprà S, Pilkington C, Maillard S, Civino A, Tsitsami E, de Inocencio J, Jelusic M, Vojinovic J, Espada G, Makay B, Katsicas MM, Pratsidou-Gertsi P, Lazarevic D, Rao AP, Pires Marafon D, Ruperto N, Martini A, Ravelli A.
    Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care.
    Arthritis Care Res (Hoboken). 2017 Dec 15. doi: 10.1002/acr.23491. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/29245175
 
NOVIEMBRE 2017
    • Schmidt K, Schmidt J.
      Inclusion body myositis: advancements in diagnosis, pathomechanisms, and treatment.
      Curr Opin Rheumatol. 2017 Nov;29(6):632-638
      https://www.ncbi.nlm.nih.gov/pubmed/28832349
    • Diederichsen LP.
      Cardiovascular involvement in myositis.
      Curr Opin Rheumatol. 2017 Nov;29(6):598-603
      https://www.ncbi.nlm.nih.gov/pubmed/28841590
    • Tansley SL, Simou S, Shaddick G, Betteridge ZE, Almeida B, Gunawardena H, Thomson W, Beresford MW, Midgley A, Muntoni F, Wedderburn LR, McHugh NJ.
      Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort.
      J Autoimmun. 2017 Nov;84:55-64
      https://www.ncbi.nlm.nih.gov/pubmed/28663002
    • Challa D, Crowson CS, Niewold TB, Reed AM; CARRA Legacy Registry Investigators.
      Predictors of changes in disease activity among children with juvenile dermatomyositis enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry.
      Clin Rheumatol. 2017 Nov 23.
      https://www.ncbi.nlm.nih.gov/pubmed/29170979
    • Bottai M, Tjärnlund A, Santoni G, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Danko K, Dimachkie MM, Feldman BM, García-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinka M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Wook Song Y, Vencovsky J, Ytterberg SR, Miller FW, Rider LG, Lundberg IE; International Myositis Classification Criteria Project consortium, the Euromyositis register and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland).
      EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report.
      RMD Open. 2017 Nov 14;3(2):e000507
      https://www.ncbi.nlm.nih.gov/pubmed/29177080
 
OCTUBRE 2017
      • Tjärnlund A, Tang Q, Wick C, Dastmalchi M, Mann H, Tomasová Studýnková J, Chura R, Gullick NJ, Salerno R, Rönnelid J, Alexanderson H, Lindroos E, Aggarwal R, Gordon P, Vencovsky J, Lundberg IE.
        Abatacept in the treatment of adult dermatomyositis and polymyositis: A randomised, phase IIb treatment delayed-start trial.
        Ann Rheum Dis. 2017 Oct 9. pii: annrheumdis-2017-211751. doi: 10.1136/annrheumdis-2017-211751. [Epub ahead of print]
        https://www.ncbi.nlm.nih.gov/pubmed/28993346
      • McCann LJ, Pilkington CA, Huber AM, Ravelli A, Appelbe D, Kirkham JJ, Williamson PR, Aggarwal A, Christopher-Stine L, Constantin T, Feldman BM, Lundberg I, Maillard S, Mathiesen P, Murphy R, Pachman LM, Reed AM, Rider LG, van Royen-Kerkof A, Russo R, Spinty S, Wedderburn LR, Beresford MW.
        Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research
        Ann Rheum Dis. 2017 Oct 30. pii: annrheumdis-2017-212141. doi: 10.1136/annrheumdis-2017-212141. [Epub ahead of print]
        https://www-ncbi-nlm-nih-gov.sire.ub.edu/pubmed/29084729
      • Li J, Liu Y, Li Y, Li F, Wang K, Pan W, Meng D.
        Associations between anti-melanoma differentiation-associated gene 5 antibody and demographics, clinical characteristics and laboratory results of patients with dermatomyositis: A systematic meta-analysis.
        J Dermatol. 2017 Oct 6. doi: 10.1111/1346-8138.14092. [Epub ahead of print]
        https://www.ncbi.nlm.nih.gov/pubmed/28983955
      • Besançon A, Brochard K, Dupic L, Gitiaux C, Delville M, Krid S, Quartier P, Saire E, Salomon R, Talbotec C, Bodemer C, Bader-Meunier B.
        Presentations and outcomes of juvenile dermatomyositis patients admitted to intensive care units.
        Rheumatology (Oxford). 2017 Oct 1;56(10):1814-1816. doi: 10.1093/rheumatology/kex267.
        https://www.ncbi.nlm.nih.gov/pubmed/28957568
      • Meneghel A, Martini G, Birolo C, Tosoni A, Pettenazzo A, Zulian F.
        Life-threatening systemic capillary leak syndrome in juvenile dermatomyositis.
        Rheumatology (Oxford). 2017 Oct 1;56(10):1822-1823. doi: 10.1093/rheumatology/kex262.
        https://www.ncbi.nlm.nih.gov/pubmed/28957546
      • McCann LJ, Pilkington CA, Huber AM, Ravelli A, Appelbe D, Kirkham JJ, Williamson PR, Aggarwal A, Christopher-Stine L, Constantin T, Feldman BM, Lundberg I, Maillard S, Mathiesen P, Murphy R, Pachman LM, Reed AM, Rider LG, van Royen-Kerkof A, Russo R, Spinty S, Wedderburn LR, Beresford MW.
        2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups
        Ann Rheum Dis. 2017 Oct 30. pii: annrheumdis-2017-212141. doi: 10.1136/annrheumdis-2017-212141. [Epub ahead of print]
        https://www-ncbi-nlm-nih-gov.sire.ub.edu/pubmed/29079590
 
SEPTIEMBRE 2017
      • Orandi AB, Baszis KW, Dharnidharka VR, Huber AM, Hoeltzel MF; CARRA Juvenile Myositis subgroup.
        Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA).
        Pediatr Rheumatol Online J. 2017 Sep 21;15(1):71. doi: 10.1186/s12969-017-0199-4.
        https://www.ncbi.nlm.nih.gov/pubmed/28934971
      • Nuño-Nuño L, Joven BE, Carreira PE, Maldonado-Romero V, Larena-Grijalba C, Cubas IL, Tomero EG, Barbadillo-Mateos MC, De la Peña Lefebvre PG, Ruiz-Gutiérrez L, López-Robledillo JC, Moruno-Cruz H, Pérez A, Cobo-Ibáñez T, Almodóvar González R, Lojo L, García De Yébenes MJ, López-Longo FJ.
        Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain.
        Rheumatol Int. 2017 Sep 2. doi: 10.1007/s00296-017-3799-x. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/28866745
      • Sharma N, Putman MS, Vij R, Strek ME, Dua A.
        Myositis-associated Interstitial Lung Disease: Predictors of Failure of Conventional Treatment and Response to Tacrolimus in a US Cohort.
        J Rheumatol. 2017 Sep 1. pii: jrheum.161217. doi: 10.3899/jrheum.161217. [Epub ahead of print]
        https://www.ncbi.nlm.nih.gov/pubmed/28864644
 
AGOSTO 2017
      • Barth Z, Witczak BN, Flatø B, Koller A, Sjaastad I, Sanner H.
        Microvascular Abnormalities Assessed by Nailfold Capillaroscopy In Juvenile Dermatomyositis After Medium to Long-Term Follow-Up.
        Arthritis Care Res (Hoboken). 2017 Aug 13. doi: 10.1002/acr.23338. [Epub ahead of print]
        https://www.ncbi.nlm.nih.gov/pubmed/28805016
      • Rider LG, Ruperto N, Pistorio A, Erman B, Bayat N, Lachenbruch PA, et al for the International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation.
        2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects.
        Rheumatology (Oxford). 2017 Aug 2. doi: 10.1093/rheumatology/kex226. [Epub ahead of print]
        https://www.ncbi.nlm.nih.gov/pubmed/28977549
 
JULIO 2017
      • Kishi T, Rider LG, Pak K, Barillas-Arias L, Henrickson M, McCarthy PL, Shaham B, Weiss PF, Horkayne-Szakaly I, Targoff IN, Miller FW, Mammen AL; Childhood Myositis Heterogeneity Study Group.
        Association of Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies With DRB1*07:01 and Severe Myositis in Juvenile Myositis Patients
        .Arthritis Care Res (Hoboken). 2017 Jul;69(7):1088-1094. doi: 10.1002/acr.23113.
        https://www.ncbi.nlm.nih.gov/pubmed/28129483
      • Mamyrova G, Rider LG, Ehrlich A, Jones O, Pachman LM, Nickeson R, Criscone-Schreiber LG, Jung LK, Miller FW, Katz JD.
        Environmental factors associated with disease flare in juvenile and adult dermatomyositis
        Rheumatology, Volume 56, Issue 8, 1 August 2017, Pages 1342–1347
        https://www.ncbi.nlm.nih.gov/pubmed/28444299
      • Cantez S, Gross GJ, MacLusky I, Feldman BM.
        Cardiac findings in children with juvenile Dermatomyositis at disease presentation.
        Pediatr Rheumatol Online J. 2017 Jul 11;15(1):54. doi: 10.1186/s12969-017-0182-0.
        https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504613/
      • Spencer CH, Rouster-Stevens K, Gewanter H, Syverson G, Modica R, Schmidt K, Emery H, Wallace C, Grevich S, Nanda K, Zhao YD, Shenoi S, Tarvin S, Hong S, Lindsley C0, Weiss JE, Passo M, Ede K, Brown A, Ardalan K, Bernal W, Stoll ML, Lang B, Carrasco R, Agaiar C, Feller L, Bukulmez H, Vehe R, Kim H, Schmeling H, Gerstbacher D, Hoeltzel M, Eberhard B, Sundel R, Kim S, Huber AM, Patwardhan A; Pediatric Rheumatologist Collaborators.
        Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America.
        Pediatr Rheumatol Online J. 2017 Jun 13;15(1):50. doi: 10.1186/s12969-017-0174-0.
        https://www.ncbi.nlm.nih.gov/pubmed/28610606
 
JUNIO 2017
      • Spencer CH, Rouster-Stevens K, Gewanter H, Syverson G, Modica R, Schmidt K, Emery H, Wallace C, Grevich S, Nanda K, Zhao YD, Shenoi S, Tarvin S, Hong S, Lindsley C, Weiss JE, Passo M, Ede K, Brown A, Ardalan K, Bernal W, Stoll ML, Lang B, Carrasco R, Agaiar C, Feller L, Bukulmez H, Vehe R, Kim H, Schmeling H, Gerstbacher D, Hoeltzel M, Eberhard B, Sundel R, Kim S, Huber AM, Patwardhan A; Pediatric Rheumatologist Collaborators.
        Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America.
        Pediatr Rheumatol Online J. 2017 Jun 13;15(1):50.
        https://www.ncbi.nlm.nih.gov/pubmed/28610606
      • Berntsen KS, Tollisen A, Schwartz T, Kirkhus E, Aaløkken TM, Lund MB, Flatø B, Sjaastad I, Sanner H.
        Submaximal Exercise Capacity in Juvenile Dermatomyositis after Longterm Disease: The Contribution of Muscle, Lung, and Heart Involvement.
        J Rheumatol. 2017 Jun;44(6):827-834.
        https://www.ncbi.nlm.nih.gov/pubmed/28365577
 
ABRIL 2017
      • Phillippi K, Hoeltzel M, Byun Robinson A, Kim S; Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry Investigators
        Race, Income, and Disease Outcomes in Juvenile Dermatomyositis.
        J Pediatr. 2017 Mar 3. pii: S0022-3476(17)30156-7. doi: 10.1016/j.jpeds.2017.01.046. [Epub ahead of print]
        https://www.ncbi.nlm.nih.gov/pubmed/28410093
      • Tiao J, Feng R, Berger EM, Brandsema JF, Coughlin CC, Khan N, Kichula EA, Lerman MA, Lvovich S, McMahon PJ, Rider LG, Rubin AI, Scalzi LV, Smith DM, Taxter AJ, Treat JR, Williams RP, Yum SW, Okawa J, Werth VP.
        Evaluation of the Reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) and the Cutaneous Assessment Tool Binary Method (CAT-BM) in Juvenile Dermatomyositis Among Pediatric Dermatologists, Rheumatologists, and Neurologists
        Br J Dermatol. 2017 Apr 19. doi: 10.1111/bjd.15596. [Epub ahead of print]
        https://www.ncbi.nlm.nih.gov/pubmed/28421601
 
MAYO 2017
      • Loaiza-Félix J, Moreno-Ramírez M, Pérez-García FL, Jiménez-Rojas V, Sánchez-Muñoz F, Amezcua-Guerra ML.
        Serum levels of adipokines in patients with idiopathic inflammatory myopathies: a pilot study.
        Rheumatol Int. 2017 May 23. [Epub ahead of print]
        https://www.ncbi.nlm.nih.gov/pubmed/?term=28536758
      • Hussain A, Rawat A, Jindal AK, Gupta A, Singh S.
        Autoantibodies in children with juvenile dermatomyositis: A single centre experience from North-West India.
        Rheumatol Int. 2017 May;37(5):807-812. doi: 10.1007/s00296-017-3707-4.
        https://www.ncbi.nlm.nih.gov/pubmed/?term=28331982
      • Hashkes PJ.
        Race and income affects outcomes in juvenile dermatomyositis.
        J Pediatr. 2017 May;184:2. doi: 10.1016/j.jpeds.2017.03.012.
        https://www.ncbi.nlm.nih.gov/pubmed/?term=28434566
      • Phillippi K, Hoeltzel M, Byun Robinson A, Kim S; Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry Investigators.
        Race, Income, and Disease Outcomes in Juvenile Dermatomyositis.
        J Pediatr. 2017 May;184:38-44.e1. doi: 10.1016/j.jpeds.2017.01.046.
        https://www.ncbi.nlm.nih.gov/pubmed/?term=28410093
 
ABRIL 2017
      • Phillippi K, Hoeltzel M, Byun Robinson A, Kim S; Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry Investigators
        Race, Income, and Disease Outcomes in Juvenile Dermatomyositis.
        J Pediatr. 2017 Mar 3. pii: S0022-3476(17)30156-7. doi: 10.1016/j.jpeds.2017.01.046. [Epub ahead of print]  https://www.ncbi.nlm.nih.gov/pubmed/28410093
      • Tiao J, Feng R, Berger EM, Brandsema JF, Coughlin CC, Khan N, Kichula EA, Lerman MA, Lvovich S, McMahon PJ, Rider LG, Rubin AI, Scalzi LV, Smith DM, Taxter AJ, Treat JR, Williams RP, Yum SW, Okawa J, Werth VP.
        Evaluation of the Reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) and the Cutaneous Assessment Tool Binary Method (CAT-BM) in Juvenile Dermatomyositis Among Pediatric Dermatologists, Rheumatologists, and Neurologists
        Br J Dermatol. 2017 Apr 19. doi: 10.1111/bjd.15596. [Epub ahead of print]
        https://www.ncbi.nlm.nih.gov/pubmed/28421601
MARZO 2017
      • Rider LG, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman BM, Huber AM, Cimaz R, Cuttica RJ, de Oliveira SK, Lindsley CB, Pilkington CA, Punaro M, Ravelli A, Reed AM, Rouster-Stevens K, van Royen-Kerkhof A, Dressler F, Magalhaes CS, Constantin T, Davidson JE, Magnusson B, Russo R, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J, Ruperto N; International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation.
        2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.
        Arthritis Rheumatol. 2017 Apr 6. doi: 10.1002/art.40060. [Epub ahead of print].
        https://www.ncbi.nlm.nih.gov/pubmed/28382778
      • Berntsen KS, Tollisen A, Schwartz T, Kirkhus E, Aaløkken TM, Lund MB, Flatø B, Sjaastad I, Sanner H.
        Submaximal Exercise Capacity in Juvenile Dermatomyositis after Longterm Disease: The Contribution of Muscle, Lung, and Heart Involvement.
        J Rheumatol. 2017 Apr 1. pii: jrheum.160997. doi: 10.3899/jrheum.160997. [Epub ahead of print]
        https://www.ncbi.nlm.nih.gov/pubmed/28365577
      • Wang CR.
        Successful Treatment of Refractory Juvenile Dermatomyositis With Adalimumab.
        J Clin Rheumatol. 2017 Apr;23(3):174-175. doi: 10.1097/RHU.0000000000000514.
        https://www.ncbi.nlm.nih.gov/pubmed/28333871
FEBRERO 2017
      • Tansley SL, Betteridge ZE, Simou S, Jacques TS, Pilkington C, Wood M, Warrier K, Wedderburn LR, McHugh NJ; Juvenile Dermatomyositis Research Group.
        Anti-HMGCR Autoantibodies in Juvenile Idiopathic Inflammatory Myopathies Identify a Rare but Clinically Important Subset of Patients.
        J Rheumatol. 2017 Feb 15. pii: jrheum.160871. doi: 10.3899/jrheum.160871. [Epub ahead of print]
        https://www.ncbi.nlm.nih.gov/pubmed/28202739
      • Montoya CL, Gonzalez ML, Ospina FE, Tobón GJ.
        A Rare Case of Amyopathic Juvenile Dermatomyositis Associated With Psoriasis Successfully Treated With Ustekinumab.
        J Clin Rheumatol. 2017 Mar;23(2):129-130. doi: 10.1097/RHU.0000000000000430.
        https://www.ncbi.nlm.nih.gov/pubmed/28099216
      • McCann LJ, Pain CE.
        A Practical Approach to Juvenile Dermatomyositis and Juvenile Scleroderma.
        Indian J Pediatr. 2016 Feb;83(2):163-71.
        https://www.ncbi.nlm.nih.gov/pubmed/26489640
ENERO 2017
      • Aggarwal R, Loganathan P, Koontz D2, Qi Z, Reed AM, Oddis CV
        Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab.
        Rheumatology (Oxford). 2017 Feb;56(2):247-254. doi: 10.1093/rheumatology/kew396. Epub 2016 Nov 11.
        https://www.ncbi.nlm.nih.gov/pubmed/27837048
      • Liang WC, Uruha A, Suzuki S, Murakami N, Takeshita E, Chen WZ, Jong YJ, Endo Y3, Komaki H, Fujii T, Kawano Y, Mori-Yoshimura M, Oya Y, Xi J, Zhu W, Zhao C, Watanabe Y, Ikemoto K, Nishikawa A, Hamanaka K, Mitsuhashi S, Suzuki N, Nishino I
        Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies.
        Rheumatology (Oxford). 2017 Feb;56(2):287-293. doi: 10.1093/rheumatology/kew386. Epub 2016 Nov 6.
        https://www.ncbi.nlm.nih.gov/pubmed/27818386
      • Kishi T, Rider LG, Pak K, Barillas-Arias L, Henrickson M, McCarthy PL, Shaham B, Weiss PF, Horkayne-Szakaly I, Targoff IN, Miller FW, Mammen AL; Childhood Myositis Heterogeneity Study Group.
        Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies are Associated with DRB1*07:01 and Severe Myositis in Pediatric Myositis Patients.
        Arthritis Care Res (Hoboken). 2017 Jan 27. doi: 10.1002/acr.23113. [Epub ahead of print]
        https://www.ncbi.nlm.nih.gov/pubmed/28129483
      • Enders FB, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, Lahdenne P, Magnusson B, Nistala K, Ozen S, Pilkington C, Ravelli A, Russo R, Uziel Y, van Brussel M, van der Net J, Vastert S, Wedderburn LR, Wulffraat N, McCann LJ, van Royen-Kerkhof A.
        Consensus-based recommendations for the management of juvenile dermatomyositis.
        Ann Rheum Dis. 2017 Feb;76(2):329-340. doi: 10.1136/annrheumdis-2016-209247. Epub 2016 Aug 11.
        https://www.ncbi.nlm.nih.gov/pubmed/27515057
NOVIEMBRE 2016
      • Ibarra M, Rigsby C, Morgan GA, Sammet CL, Huang CC, Xu D, Targoff IN, Pachman LM.
        Monitoring change in volume of calcifications in juvenile idiopathic inflammatory myopathy: a pilot study using low dose computed tomography.
        Pediatr Rheumatol Online J. 2016 Nov 29;14(1):64.
        https://www.ncbi.nlm.nih.gov/pubmed/27894310
      • Huber AM, Kim S, Reed AM, Carrasco R, Feldman BM, Hong SD, Kahn P, Rahimi H, Robinson AB, Vehe RK, Weiss JE, Spencer C; and the Juvenile Dermatomyositis Research Committee of the Childhood Arthritis and Rheumatology Research Alliance.
        Childhood Arthritis and Rheumatology Research Alliance Consensus Clinical Treatment Plans for Juvenile Dermatomyositis with Persistent Skin Rash.
        J Rheumatol. 2016 Nov 1.
        https://www.ncbi.nlm.nih.gov/pubmed/27803135
      • López De Padilla CM, Crowson CS, Hein MS, Pendegraft RS, Strausbauch MA, Niewold TB, Ernste FC, Peterson E, Baechler EC, Reed AM.
        Gene Expression Profiling in Blood and Affected Muscle Tissues Reveals Differential Activation Pathways in Patients with New-onset Juvenile and Adult Dermatomyositis.
        J Rheumatol. 2016 Nov 1.
        https://www.ncbi.nlm.nih.gov/pubmed/27803134
 
OCTUBRE 2016
      • Deakin CT, Yasin SA, Simou S, Arnold KA, Tansley SL, Betteridge ZE, McHugh NJ, Varsani H, Holton JL, Jacques TS, Pilkington CA, Nistala K, Wedderburn LR; UK Juvenile Dermatomyositis Research Group..
        Muscle Biopsy Findings in Combination With Myositis-Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis.
        Arthritis Rheumatol. 2016 Nov;68(11):2806-2816. doi: 10.1002/art.39753
        https://www.ncbi.nlm.nih.gov/pubmed/27214289
 
SEPTIEMBRE 2016
 
AGOSTO 2016
      • Tansley SL.
        Antibodies in juvenile-onset myositis.
        Curr Opin Rheumatol. 2016 Nov;28(6):645-650.
        http://www.ncbi.nlm.nih.gov/pubmed/27533322
      • Speth F, Haas JP, Hinze CH.
        Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases.
        Pediatr Rheumatol Online J. 2016 Sep 13;14(1):52.
        http://www.ncbi.nlm.nih.gov/pubmed/27623619
      • Paik JJ, Christopher-Stine L.
        A case of refractory dermatomyositis responsive to tofacitinib
        Semin Arthritis Rheum 2016 Epub
        http://www.semarthritisrheumatism.com/article/S0049-0172(16)30200-1/abstract
      • Fotis L, Baszis KW, White AJ, French AR.
        Four Cases of Anti-PM/Scl Antibody-positive Juvenile Overlap Syndrome with Features of Myositis and Systemic Sclerosis.
        J Rheumatol. 2016 Sep;43(9):1768-9.
        http://www.ncbi.nlm.nih.gov/pubmed/27587018
      • Li T, Guo L, Chen Z, Gu L, Sun F, Tan X, Chen S, Wang X, Ye S.
        Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis.
        Sci Rep. 2016 Sep 12;6:33226.
        http://www.ncbi.nlm.nih.gov/pubmed/27615411
      • Sato S, Uejima Y, Nanbu M, Suganuma E, Takano T, Tanaka R, Kabuki T, Oguma E, Oh-Ishi T, Kawano Y.
        Clinical analysis and outcome of interstitial lung disease complicated with juvenile dermatomyositis and juvenile polymyositis.
        Mod Rheumatol. 2016 Sep 20:1-5. [Epub ahead of print]
        http://www.ncbi.nlm.nih.gov/pubmed/27588444
 
JUNIO 2016
      • Leverenz D, Zaha O, Crofford LJ, Chung CP.
        Causes of creatine kinase levels greater than 1000 IU/L in patients referred to rheumatology.
        Clin Rheumatol. 2016 Jun;35(6):1541-7. doi: 10.1007/s10067-016-3242-9.
        http://www.ncbi.nlm.nih.gov/pubmed/27041384
 
ABRIL 2016
      • Preuße C, Allenbach Y, Hoffmann O, Goebel HH, Pehl D, Radke J, Doeser A, Schneider U, Alten RH, Kallinich T, Benveniste O, von Moers A, Schoser B, Schara U, Stenzel W.
        Differential roles of hypoxia and innate immunity in juvenile and adult dermatomyositis.
        Acta Neuropathol Commun. 2016 Apr 27;4(1):45. doi: 10.1186/s40478-016-0308-5.
        http://www-ncbi-nlm-nih-gov.sire.ub.edu/pubmed/27121733
      • Pinto AJ, Yazigi Solis M, de Sá Pinto AL, Silva CA, Maluf Elias Sallum A, Roschel H, Gualano B.
        Physical (in)activity and its influence on disease-related features, physical capacity, and health-related quality of life in a cohort of chronic juvenile dermatomyositis patients.
        Semin Arthritis Rheum. 2016 Mar 18. pii: S0049-0172(16)00102-5. doi: 10.1016/j.semarthrit.2016.03.010. 
        http://www-ncbi-nlm-nih-gov.sire.ub.edu/pubmed/27113390
 
MARZO 2016
      • Rider LG, Nistala K.
        The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes.
        J Intern Med. 2016 Mar 30. doi: 10.1111/joim.12444. [Epub ahead of print]
        http://www.ncbi.nlm.nih.gov/pubmed/27028907
      • de Inocencio J, Enríquez-Merayo E, Casado R, González-Granado LI.
        Subcutaneous Immunoglobulin in Refractory Juvenile Dermatomyositis.
        Pediatrics. 2016 Mar 10. pii: peds.2015-3537. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26966131
      • Salman A, Kasapcopur O, Ergun T, Durmus Ucar AN, Demirkesen C.
        Panniculitis in juvenile dermatomyositis: Report of a case and review of the published work.
        J Dermatol. 2016 Mar 12. doi: 10.1111/1346-8138.13335. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26971888
      • Saini I, Kalaivani M, Kabra SK.
        Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome.
        Rheumatol Int. 2016 Mar 23. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/27007612
      • Habers GE, Bos GJ, van Royen-Kerkhof A, Lelieveld OT, Armbrust W, Takken T, van Brussel M.
        Muscles in motion: a randomized controlled trial on the feasibility, safety and efficacy of an exercise training programme in children and adolescents with juvenile dermatomyositis.
        Rheumatology (Oxford). 2016 Mar 27. pii: kew026. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/27018060
      • Pinto AJ, Roschel H, Benatti FB, de Sá Pinto AL, Sallum AM, Silva CA, Gualano B.
        Poor agreement of objectively measured and self-reported physical activity in juvenile dermatomyositis and juvenile systemic lupus erythematosus.
        Clin Rheumatol. 2016 Mar 28. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/27021334
 
FEBRERO 2016
      • Campanilho-Marques R, Almeida B, Deakin C, Arnold K, Gallot N, de Iorio M, Nistala K, Pilkington CA, Wedderburn LR; Juvenile Dermatomyositis Research Group (JDRG).
        Comparison of the utility and validity of three scoring tools to measure skin involvement in patients with Juvenile Dermatomyositis.
        Arthritis Care Res (Hoboken). 2016 Feb 16. doi: 10.1002/acr.22867. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26881696
      • Alexanderson H.
        Physical exercise as a treatment for adult and juvenile myositis.
        J Intern Med. 2016 Feb 8. doi: 10.1111/joim.12481. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26854121
      • Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, Fischbach M, Magnusson B, Sterba G, Avcin T, Brochard K, Corona F, Dressler F, Gerloni V, Apaz MT, Bracaglia C, Cespedes-Cruz A, Cimaz R, Couillault G, Joos R, Quartier P, Russo R, Tardieu M, Wulffraat N,Bica B, Dolezalova P, Ferriani V, Flato B, Bernard-Medina AG, Herlin T, Trachana M, Meini A, Allain-Launay E, Pilkington C, Vargova V,Wouters C, Angioloni S, Martini A; Paediatric Rheumatology International Trials Organisation (PRINTO).
        Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial.
        Lancet. 2016 Feb 13;387(10019):671-8. doi: 10.1016/S0140-6736(15)01021-1. Epub 2015 Nov 30.
        http://www.ncbi.nlm.nih.gov/pubmed/26645190
 
NOVIEMBRE 2015
      • G Esther A Habers, Adam M Huber, Gulnara Mamyrova, Ira N Targoff, Terrance P O'Hanlon, Sharon Adams, Janardan P Pandey, Chantal Boonacker, Marco van Brussel, Frederick W Miller, Annet van Royen-Kerkhof, Lisa G Rider and Childhood Myositis Heterogeneity Study Group
        Myositis autoantibodies, clinical features, and environmental exposures at illness onset are associated with disease course in juvenile myositis

        Arthritis & Rheumatology DOI: 10.1002/art.39466
        Abstract
      • Tansley, Sarah; Wedderburn, Lucy R.
        Comparing and contrasting clinical and serological features of juvenile and adult-onset myositis: implications for pathogenesis and outcomes

        Current Opinion in Rheumatology:
        November 2015 - Volume 27 - Issue 6 - p 601–607
        doi: 10.1097/BOR.0000000000000224 
      • Hiroyuki Wakiguchi, Shunji Hasegawa, Reiji Hirano, Hidenobu Kaneyasu, Midori Wakabayashi-Takahara, Shouichi Ohga
        Successful control of juvenile dermatomyositis-associated macrophage activation syndrome and interstitial pneumonia: distinct kinetics of interleukin-6 and -18 levels
        Pediatric Rheumatology 2015, 13:49 (18 November 2015)
        Abstract
 
OCTUBRE 2015
      • Habers GE, Huber AM, Mamyrova G, Targoff IN, O'Hanlon TP, Adams S, Pandey JP, Boonacker C, van Brussel M, Miller FW, van Royen-Kerkhof A, Rider LG; Childhood Myositis Heterogeneity Study Group.
        Myositis autoantibodies, clinical features, and environmental exposures at illness onset are associated with disease course in juvenile myositis.
        Arthritis Rheumatol. 2015 Oct 16. doi: 10.1002/art.39466.
        http://www.ncbi.nlm.nih.gov/pubmed/26474155
      • Tansley S, Wedderburn LR.
        Comparing and contrasting clinical and serological features of juvenile and adult-onset myositis: implications for pathogenesis and outcomes
        Curr Opin Rheumatol. 2015 Nov;27(6):601-7. doi: 10.1097/BOR.0000000000000224.
        http://www.ncbi.nlm.nih.gov/pubmed/26352731
      • Barth Z, Nomeland Witczak B, Schwartz T, Gjesdal K, Flatø B, Koller A, Sanner H, Sjaastad I.
        In juvenile dermatomyositis, heart rate variability is reduced, and associated with both cardiac dysfunction and markers of inflammation: a cross-sectional study median 13.5 years after symptom onset.
        Rheumatology (Oxford). 2015 Oct 24. pii: kev376. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26500284
      • Pagnini I, Vitale A, Selmi C, Cimaz R, Cantarini L.
        Idiopathic Inflammatory Myopathies: an Update on Classification and Treatment with Special Focus on Juvenile Forms
        Clin Rev Allergy Immunol. 2015 Oct 1. [Epub ahead of print]
        http://www.ncbi.nlm.nih.gov/pubmed/26429707
 
SEPTIEMBRE 2015
      • Miller FW, Chen W, O'Hanlon TP, Cooper RG, Vencovsky J, Rider LG, Danko K, Wedderburn LR, Lundberg IE, Pachman LM, Reed AM, Ytterberg SR, Padyukov L, Selva-O'Callaghan A, Radstake TR, Isenberg DA, Chinoy H, Ollier WE, Scheet P, Peng B, Lee A, Byun J, Lamb JA, Gregersen PK, Amos CI.
        Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes.
        Genes Immun. 2015 Oct;16(7):470-80. doi: 10.1038/gene.2015.28.
        http://www.ncbi.nlm.nih.gov/pubmed/26291516
      • Rothwell S, Cooper RG, Lundberg IE, Miller FW, Gregersen PK, Bowes J, Vencovsky J, Danko K, Limaye V, Selva-O'Callaghan A, Hanna MG, Machado PM, Pachman LM, Reed AM, Rider LG, Cobb J, Platt H, Molberg Ø, Benveniste O, Mathiesen P, Radstake T, Doria A, De Bleecker J, De Paepe B, Maurer B, Ollier WE, Padyukov L, O'Hanlon TP, Lee A, Amos CI, Gieger C, Meitinger T, Winkelmann J, Wedderburn LR, Chinoy H, Lamb JA; Myositis Genetics Consortium.
        Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups.
        Ann Rheum Dis. 2015 Sep 11. pii: annrheumdis-2015-208119. doi: 10.1136/annrheumdis-2015-208119. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26362759 
 
AGOSTO 2015
      • van Brussel M, van Oorschot JW, Schmitz JP, Nicolay K, van Royen-Kerkhof A, Takken T, Jeneson JA.
        Muscle Metabolic Responses During Dynamic In-Magnet Exercise Testing: A Pilot Study in Children with an Idiopathic Inflammatory Myopathy.
        Acad Radiol. 2015 Aug 7. doi:10.1016/j.acra.2015.06.013. EPUB
        ahead of print]
        http://www.ncbi.nlm.nih.gov/pubmed/26259546
      • Cañas CA, Bonilla-Abadía F, Mejía M, Tobón GJ.
        Recovery of Severe Muscular and Fascial Calcinosis After Treatment With Bisphosphonates in a Child With Juvenile Dermatomyositis.
        J Clin Rheumatol. 2015 Aug;21(5):267-9. doi:10.1097/RHU.0000000000000264.
        http://www.ncbi.nlm.nih.gov/pubmed/26203832
      • Almeida B, Campanilho-Marques R, Arnold K, Pilkington CA, Wedderburn LR, Nistala K; Juvenile Dermatomyositis Research Group.
        Analysis of Published Criteria for Clinically Inactive Disease in a Large Juvenile Dermatomyositis Cohort Shows That Skin Disease Is Underestimated.
        Arthritis Rheumatol. 2015 Sep;67(9):2495-502. doi:10.1002/art.39200.
        http://www.ncbi.nlm.nih.gov/pubmed/25988361
 
JUNIO 2015
      • Lightfoot AP, McArdle A, Jackson MJ, Cooper RG.
        In the idiopathic inflammatory myopathies (IIM), do reactive oxygen species (ROS) contribute to muscle weakness?
        Ann Rheum Dis. 2015 Jul;74(7):1340-1346. doi: 10.1136/annrheumdis-2014-207172. Review.
        http://www.ncbi.nlm.nih.gov/pubmed/26063809
      •  Iglesias E, Bou R, Torrente-Segarra V, Antón J.
        Importancia de un estudio basal completo en pacientes con diagnóstico de dermatomiositis juvenil
        An Pediatr (Barc). 2015 Jun;82(6):449-50. doi: 10.1016/j.anpedi.2015.01.011.
        http://www.ncbi.nlm.nih.gov/pubmed/25746608
 
MAYO 2015
      • Norimoto Kobayashi, Shunichiro Takezaki, Ichiro Kobayashi, Naomi Iwata, Masaaki Mori, Kazushige Nagai, Naoko Nakano, Mari Miyoshi, Noriko Kinjo, Takuji Murata, Kenji Masunaga, Hiroaki Umebayashi, Tomoyuki Imagawa, Kazunaga Agematsu, Shinji Sato, Masataka Kuwana, Masafumi Yamada, Shuji Takei, Shumpei Yokota, Kenichi Koike, and Tadashi Ariga
        Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis
        Rheumatology (2015) 54 (5): 784-791 doi:10.1093/rheumatology/keu385
        http://rheumatology.oxfordjournals.org/content/54/5/784.abstract
ABRIL 2015
 
MARZO 2015
FEBRERO 2015
      • Otero Rivas MM, Vicente Villa A, González Lara L, Suñol Capella M, Antón López J, González Enseñat MA.
        Panniculitis in juvenile dermatomyositis.
        Clin Exp Dermatol. 2015 Feb 16.
        http://www.ncbi.nlm.nih.gov/pubmed/25682744
      • Hung CH.
        Treatment and clinical outcome of juvenile dermatomyositis.
        Pediatr Neonatol. 2015 Feb;56(1):1-2.
        http://www.ncbi.nlm.nih.gov/pubmed/25487198
 
ENERO 2015
      • Varsani H, Charman SC, Li CK, Marie SK, Amato AA, Banwell B, Bove KE, Corse AM, Emslie-Smith AM, Jacques TS, Lundberg IE, Minetti C, Nennesmo I, Rushing EJ, Sallum AM, Sewry C, Pilkington CA, Holton JL, Wedderburn LR; UK Juvenile Dermatomyositis Research Group.
        Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease.
        Ann Rheum Dis. 2015 Jan;74(1):204-10. doi: 10.1136/annrheumdis-2013-203396. Epub 2013 Sep 24.
        http://www.ncbi.nlm.nih.gov/pubmed/24064003
 
DICIEMBRE 2014
 
NOVIEMBRE 2014
      • Palaniappan P, Lionel AP, Kumar S.
        Successful treatment of calcinosis cutis in juvenile dermatomyositis with pamidronate.
        J Clin Rheumatol. 2014 Dec;20(8):454-5.
        http://www.ncbi.nlm.nih.gov/pubmed/?term=24996906
      • Hoeltzel MF, Oberle EJ, Robinson AB, Agarwal A, Rider LG.
        The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis.
        Curr Rheumatol Rep. 2014 Dec;16(12):467.
        http://www.ncbi.nlm.nih.gov/pubmed/?term=25366934
      • Bailey EE, Fiorentino DF.
        Amyopathic dermatomyositis: definitions, diagnosis, and management.
        Curr Rheumatol Rep. 2014 Dec;16(12):465
        http://www.ncbi.nlm.nih.gov/pubmed/?term=25366932
      • Cappelletti C, Galbardi B, Kapetis D, Vattemi G, Guglielmi V, Tonin P, Salerno F, Morandi L, Tomelleri G, Mantegazza R, Bernasconi P.
        Autophagy, inflammation and innate immunity in inflammatory myopathies.
        PLoS One. 2014 Nov 3;9(11):e111490.
        http://www.ncbi.nlm.nih.gov/pubmed/?term=25365350
      • Singh S, Suri D, Aulakh R, Gupta A, Rawat A, Kumar RM.
        Mortality in children with juvenile dermatomyositis: two decades of experience from a single tertiary care centre in North India.
        Clin Rheumatol. 2014 Nov;33(11):1675-9.
        http://www.ncbi.nlm.nih.gov/pubmed/?term=25053380
      • Schwartz T, Sjaastad I, Flatø B, Vistnes M, Christensen G, Sanner H.
        In active juvenile dermatomyositis, elevated eotaxin and MCP-1 and cholesterol levels in the upper normal range are associated with cardiac dysfunction.
        Rheumatology (Oxford). 2014 Dec;53(12):2214-22.
        http://www.ncbi.nlm.nih.gov/pubmed/?term=24996906
      • Tansley SL, Betteridge ZE, Shaddick G, Gunawardena H, Arnold K, Wedderburn LR, McHugh NJ; Juvenile Dermatomyositis Research Group.
        Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.
        Rheumatology (Oxford). 2014 Dec;53(12):2204-8.
        http://www.ncbi.nlm.nih.gov/pubmed/?term=24987158
      • Gerhold K, Becker MO.
        Nailfold capillaroscopy in juvenile rheumatic diseases: known measures, patterns and indications.
        Clin Exp Rheumatol. 2014 Nov-Dec;32 Suppl 86(6):183-8.
        http://www.ncbi.nlm.nih.gov/pubmed/?term=24960119
      • Pavlov-Dolijanovic SR, Vujasinovic Stupar NZ, Gavrilov N, Seric S.
        Lower extremity lipedema, upper extremity lipodystrophy and severe calcinosis complicating juvenile dermatomyositis.
        Rheumatol Int. 2014 Nov;34(11):1615-8.
        http://www.ncbi.nlm.nih.gov/pubmed/?term=24789670
      • Ernste FC, Reed AM.
        Recent advances in juvenile idiopathic inflammatory myopathies
        Curr Opin Rheumatol. 2014 Nov;26(6):671-8. doi: 10.1097/BOR.0000000000000103.
        http://www.ncbi.nlm.nih.gov/pubmed/25160931
OCTUBRE 2014
      • Kobayashi N, Takezaki S, Kobayashi I, Iwata N, Mori M, Nagai K, Nakano N, Miyoshi M, Kinjo N, Murata T, Masunaga K, Umebayashi H, Imagawa T, Agematsu K, Sato S, Kuwana M, Yamada M, Takei S, Yokota S, Koike K, Ariga T.
        Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis.
        Rheumatology (Oxford). 2014 Oct 6. pii: keu385. [Epub ahead of print]
        http://www.ncbi.nlm.nih.gov/pubmed/25288783 
      • Ernste, Floranne C.; Reed, Ann M.
        Recent advances in juvenile idiopathic inflammatory myopathies
        Current Opinion in Rheumatology. Nov 2014.
        doi: 10.1097/BOR.0000000000000103
        http://journals.lww.com/co-rheumatology/Abstract/2014/11000/Recent_advances_in_juvenile_idiopathic.12.aspx
 
SEPTIEMBRE 2014
      • Sanner H, Sjaastad I, FlatØ B.
        Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool.
        Rheumatology (2014);53(9):1578-1585.
        http://rheumatology.oxfordjournals.org/content/53/9/1578.abstract
      • Unger L, Kampf S, Lüthke K, Aringer M.
        Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population
        Rheumatology (2014);53(9):1630-1638
        http://rheumatology.oxfordjournals.org/content/53/9/1630.abstract
      • Castro T, Lederman H, Terreri M, Caldana W, Zanoteli E, Hilário M.
        Whole-body magnetic resonance imaging in the assessment of muscular involvement in juvenile dermatomyositis/polymyositis patients.
        Scand J Rheumatol. 2014;43(4):329-33.
        http://www.ncbi.nlm.nih.gov/pubmed/25087579
 
AGOSTO 2014
      • Vercoulen Y, Bellutti Enders F, Meerding J, Plantinga M, Elst EF, Varsani H, van Schieveen C, Bakker MH, Klein M, Scholman RC, Spliet W, Ricotti V, Koenen HJ, de Weger RA, Wedderburn LR, van Royen-Kerkhof A, Prakken BJ.
        Increased Presence of FOXP3+ Regulatory T Cells in Inflamed Muscle of Patients with Active Juvenile Dermatomyositis Compared to Peripheral Blood.
        PLoS One. 2014 Aug 26;9(8):e105353. doi: 10.1371/journal.pone.0105353. eCollection 2014.
        http://www.ncbi.nlm.nih.gov/pubmed/25157414
 
JULIO 2014
      • Rider LG, Yip AL, Horkayne-Szakaly I, Volochayev R, Shrader JA, Turner ML, Kong HH, Jain MS, Jansen AV, Oddis CV, Fleisher TA, Miller FW.
        Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial.
        Clin Exp Rheumatol. 2014 Jul 28. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/25068290
      • Schwartz T1, Sjaastad I2, Flatø B3, Vistnes M3, Christensen G4, Sanner H5.
        In active juvenile dermatomyositis, elevated eotaxin and MCP-1 and cholesterol levels in the upper normal range are associated with cardiac dysfunction.
        Rheumatology (Oxford). 2014 Jul 4. pii: keu256. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/24996906
      • Boccaletti V1, Di Nuzzo S, Feliciani C, Fabrizi G, Pagliarello C.
        An update on juvenile dermatomyositis.
        G Ital Dermatol Venereol. 2014 Jul 18. 
        http://www.ncbi.nlm.nih.gov/pubmed/25034096
      • Singh S1, Suri D, Aulakh R, Gupta A, Rawat A, Kumar RM.
        Mortality in children with juvenile dermatomyositis: two decades of experience from a single tertiary care centre in North India.
        Clin Rheumatol. 2014 Jul 23.
        http://www.ncbi.nlm.nih.gov/pubmed/25053380
      • Yu HH1, Chang HM2, Chiu CJ3, Yang YH1, Lee JH1, Wang LC1, Lin YT1, Chiang BL4.
        Detection of anti-p155/140, anti-p140, and antiendothelial cells autoantibodies in patients with juvenile dermatomyositis.
        J Microbiol Immunol Infect. 2014 Jul 25. 
        http://www.ncbi.nlm.nih.gov/pubmed/25070283
      • McCann LJ1, Arnold K2, Pilkington CA3, Huber AM4, Ravelli A5, Beard L2, Beresford MW6, Wedderburn LR7.
        Developing a provisional, international Minimal Dataset for Juvenile Dermatomyositis: for use in clinical practice to inform research.
        Pediatr Rheumatol Online J. 2014 Jul 21;12:31. doi: 10.1186/1546-0096-12-31. eCollection 2014.
        http://www.ncbi.nlm.nih.gov/pubmed/25075205
      • Tansley SL1, Betteridge ZE1, Shaddick G1, Gunawardena H1, Arnold K2, Wedderburn LR2, McHugh NJ3; on behalf of the Juvenile Dermatomyositis Research Group.
        Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.
        Rheumatology (Oxford). 2014 Jul 1. pii: keu259. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/24987158
      • Tansley SL, Betteridge ZE, Gunawardena H, Jacques TS, Owens CM, Pilkington C, Arnold K, Yasin S, Moraitis E, Wedderburn LR, McHugh NJ.
        Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study.
        Arthritis Res Ther. 2014 Jul 2;16(4):R138. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/24989778
      • Rheumatology (Oxford). 2014 Jul 1. pii: keu259. [Epub ahead of print]Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.
        Tansley SL1, Betteridge ZE1, Shaddick G1, Gunawardena H1, Arnold K2, Wedderburn LR2, McHugh NJ3; on behalf of the Juvenile Dermatomyositis Research Group.
        http://www.ncbi.nlm.nih.gov/pubmed/24987158
      • Tansley SL, Betteridge ZE, Gunawardena H, Jacques TS, Owens CM, Pilkington C, Arnold K, Yasin S, Moraitis E, Wedderburn LR, McHugh NJ.
        Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study.
        Arthritis Res Ther. 2014 Jul 2;16(4):R138. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/24989778
 
JUNIO 2014
      • Fujisawa T, Hozumi H, Kono M, Enomoto N, Hashimoto D, Nakamura Y, Inui N, Yokomura K, Koshimizu N, Toyoshima M, Shirai T, Yasuda K, Hayakawa H, Suda T.
        Prognostic factors for myositis-associated interstitial lung disease
        PLoS One. 2014 Jun 6;9(6):e98824. doi: 10.1371/journal.pone.0098824. eCollection 2014.
        http://www.ncbi.nlm.nih.gov/pubmed/24905449
      • Neri R, Barsotti S, Iacopetti V, Tripoli A, dʼAscanio A, Tavoni AG, Mosca M, Bombardieri S.
        Clinically amyopathic dermatomyositis: analysis of a monocentric cohort.
        J Clin Neuromuscul Dis. 2014 Jun;15(4):157-60. doi: 10.1097/CND.0000000000000038.
        http://www.ncbi.nlm.nih.gov/pubmed/24872214
 
MAYO2014
      • Valenzuela A, Chung L, Casciola-Rosen L, Fiorentino D.
        Identification of Clinical Features and Autoantibodies Associated With Calcinosis in Dermatomyositis.
        JAMA Dermatol. 2014 May 28. doi: 10.1001/jamadermatol.2013.10416. [Epub ahead of print]
      • Article in French
        Pouessel G1, Thumerelle C2, Nève V3, Santangelo T4, Flammarion S1, Pruvot I5, Tillie-Leblond I6, Deschildre A7.
        Lung is also involved in juvenile dermatomyositis.
        Rev Med Interne. 2014 May 21.[Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/24856457
MARZO 2014
      • Robinson AB1, Hoeltzel MF, Wahezi DM, Becker ML, Kessler EA, Schmeling H, Carrasco R, Huber AM, Feldman BM, Reed AM; Juvenile Myositis CARRA Subgroup, for the CARRA Registry Investigators.
        Clinical characteristics of children with juvenile dermatomyositis: the childhood arthritis and rheumatology research alliance registry.
        Arthritis Care Res (Hoboken). 2014 Mar;66(3):404-10. doi: 10.1002/acr.22142.
        http://www.ncbi.nlm.nih.gov/pubmed/23983017
      • Aggarwal R1, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, Miller FW, Rider LG, Harris-Love MO, Levesque MC; RIM Study Group, Oddis CV.
        Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis.
        Arthritis Rheumatol. 2014 Mar;66(3):740-9. doi: 10.1002/art.38270.
        http://www.ncbi.nlm.nih.gov/pubmed/24574235
 
FEBRERO 2014
      • McCrea N, Al-Sabbagh A, Ahmed S, Walker D, Rangaraj S.
        Onset of juvenile dermatomyositis following varicella infection in a 12-month-old child: a case report.
        J Med Case Rep. 2014 Feb 15;8(1):54. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/24529167
DICIEMBRE 2013
      • Mamyrova G, Katz JD, Jones RV, Targoff IN, Lachenbruch PA, Jones OY, Miller FW, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group.
        Clinical and laboratory features distinguishing juvenile polymyositis and muscular dystrophy.
        Arthritis Care Res (Hoboken). 2013 Dec;65(12):1969-75. doi: 10.1002/acr.22088.
        http://www.ncbi.nlm.nih.gov/pubmed/23925923
 
NOVIEMBRE 2013
 
OCTUBRE 2013
      • Huber AM, Mamyrova G, Lachenbruch PA, Lee JA, Katz JD, Targoff IN, Miller FW, Rider LG; for the Childhood Myositis Heterogeneity Study Group.
        Early Illness Features Associated with Mortality in The Juvenile Idiopathic Inflammatory Myopathies.
        Arthritis Care Res (Hoboken). 2013 Oct 21.[Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/24151254
SEPTIEMBRE 2013
      • Prestridge A, Morgan G, Ferguson L, Huang CC, Pachman LM.
        Pulmonary Function Tests in Idiopathic Inflammatory Myopathy: Association With Clinical Parameters in Children
        Arthritis Care Res 2013 Sep; 65(9):1424-31.
        http://onlinelibrary.wiley.com/doi/10.1002/acr.22014/abstract
      • Robinson AB, Hoeltzel MF, Wahezi DM, Becker ML, Kessler E, Schmeling H, Carrasco R, Huber AM, Feldman BM, Reed AM; Juvenile Myositis CARRA Subgroup; CARRA Registry Investigators.
        Clinical characteristics of children with juvenile dermatomyositis - the children's arthritis and rheumatology research alliance (CARRA) registry.
        Arthritis Care Res (Hoboken). 2013 Aug 27. doi: 10.1002/acr.22142. [Epub ahead of print]
JULIO 2013
      • Martillotti J, Moote D, Zemel L.
        Improvement of calcinosis using pamidronate in a patient with juvenile dermatomyositis.
        Pediatr Radiol. 2013 Jul 10. [Epub ahead of print]
 
MAYO 2013
      • Malattia C, Damasio MB, Madeo A, Pistorio A, Providenti A, Pederzoli S, Viola S, Buoncompagni A, Mattiuz C, Beltramo A, Consolaro A, Ravelli A, Ruperto N, Picco P, Magnano GM, Martini A
        Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis
        Ann Rheum Dis 2013 May 1. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/23636654
      • Quiñones R, Morgan GA, Amoruso M, Field R, Huang CC, Pachman LM.
        Four-year-olds, healthy or recovering from Juvenile Dermatomyositis, do not achieve a full score on the Childhood Myositis Assessment Scale (CMAS).
        Arthritis Care Res (Hoboken) 2013 May 10:NA. doi: 10.1002/acr.22041. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/23666925
      • Shah M, Targoff IN, Rice MM, Miller FW, Rider LG; with the Childhood Myositis Heterogeneity Collaborative Study Group.
        Ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in Juvenile Myositis.
        Arthritis Rheum 2013 May 8. doi: 10.1002/art.37985. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/23658122
      • Lazarevic D, Pistorio A, Palmisani E, Miettunen P, Ravelli A, Pilkington C, Wulffraat NM, Malattia C, Garay SM, Hofer M, Quartier P, Dolezalova P, Penades IC, Ferriani VP, Ganser G, Kasapcopur O, Melo-Gomes JA, Reed AM, Wierzbowska M, Rider LG, Martini A, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO).
        The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis
        Ann Rheum Dis. 2013 May;72:686-93. doi: 10.1136/annrheumdis-2012-201483.
        http://www.ncbi.nlm.nih.gov/pubmed/22736096
FEBRERO 2013
      • Mathiesen PR, Ørngreen MC, Vissing J, Andersen LB, Herlin T, Nielsen S.
        Aerobic fitness after JDM--a long-term follow-up study.
        Rheumatology (Oxford). 2013 Feb;52(2):287-95. doi: 10.1093/rheumatology/kes232. Epub 2012 Sep 22.
        http://www.ncbi.nlm.nih.gov/pubmed/23001614
      • Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE for the Rituximab in Myositis (RIM) Study Group.
        Rituximab in the treatment of refractory adult and juvenile dermatomiositis and adult polymyositis: A randomized, placebo-phase trial.
        Arthritis Rheum. 2013 Feb;65(2):314-24. doi: 10.1002/art.37754.
ENERO 2013
      • Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, Miller FW, Rider LG; with the Childhood Myositis Heterogeneity Collaborative Study Group.
        The Clinical Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies.
        Medicine (Baltimore). 2013 Jan;92(1):25-41.
        http://www.ncbi.nlm.nih.gov/pubmed/23263716
 
DICIEMBRE 2012
      • Pouessel G, Deschildre A, Le Bourgeois M, Cuisset JM, Catteau B, Karila C, Nève V, Thumerelle C, Quartier P, Tillie-Leblond I.
        The lung is involved in juvenile dermatomyositis.
        Pediatr Pulmonol. 2012 Dec 31. doi: 10.1002/ppul.22742. [Epub ahead of print]http://onlinelibrary.wiley.com/doi/10.1002/ppul.22742/pdf
      • Reed AM, Peterson E, Bilgic H. Ytterberg SR, Amin S, Hein MS, Crowson CS, Ernste F, Gillespie EB.
        Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course.
        Arthritis Rheum 2012 Dec; 64(12):4078–86. DOI: 10.1002/art.34659.
        http://onlinelibrary.wiley.com/doi/10.1002/art.34659/abstract
SEPTIEMBRE 2012
      • Patwardhan A, Rennebohm RM, Dvorchik I, Spencer CH.
        Is juvenile dermatomiositis a different disease in children up to three years of age at onset than in children above three years at onset? A retrospective review of 23 years of single center experience.
        Pediatr Rheumatol Online J. 2012 Sep 20;10(1):34. [Epub ahead of print].
        http://www.ncbi.nlm.nih.gov/pubmed/22995763
ABRIL 2012
      • Huber AM, Robinson AB, Reed AM, Abramson L, Bout-Tabaku S, Carrasco R, Curran M, Feldman BM, Gewanter H, Griffin T, Haines K, Hoeltzel MF, Isgro J, Kahn P, Lang B, Lawler P, Shaham B, Schmeling H, Scuccimarri R, Shishov M, Stringer E, Wohrley J, Ilowite NT, Wallace C; Juvenile Dermatomyositis Subcommittee of the Childhood Arthritis and Rheumatology Research Alliance.
        Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference.
        Arthritis Care Res (Hoboken). 2012 Apr;64(4):546-53. doi: 10.1002/acr.20695.
        http://www.ncbi.nlm.nih.gov/pubmed/22076847
PATROCINADORES